Tetra Pharm Technologies

Tetra Pharm Technologies TPT0701: Novel Appetite Suppressant

Tetra Pharm Technologies Advances CB1 Antagonist TPT0701 for Appetite Suppression into Preclinical Testing

Staff Reporter February 8, 2024 0

Following the successful filing of the Intellectual Property (IP) for its applied platform technology targeting the endocannabinoid system (ECS), Tetra...

Tetra Pharm Technologies and Glysious Announce Collaboration to Develop Transdermal Combination Drugs Targeting the Endocannabinoid System

Tetra Pharm Technologies Advances CB1 Antagonist TPT0701 for Appetite Suppression into Preclinical Testing

Sculpt Clinics Introduces New Laser Hair Removal Technology

HEAL Foundation Announces Healthcare CSR Summit & Awards in New Delhi

Apsara Ice Creams to launch Muskaan initiative on its 53rd anniversary

Milann Fertility Center Celebrates World Breastfeeding Week with ‘Milann’s Embrace’ Initiative

DCN Dx to Showcase New Technologies at NextGen Dx 2024

Tetra Pharm Technologies and Glysious Announce Collaboration to Develop Transdermal Combination Drugs Targeting the Endocannabinoid System

Tetra Pharm Technologies Advances CB1 Antagonist TPT0701 for Appetite Suppression into Preclinical Testing

Interesting Stories For You

Sculpt Clinics Introduces New Laser Hair Removal Technology

HEAL Foundation Announces Healthcare CSR Summit & Awards in New Delhi

Apsara Ice Creams to launch Muskaan initiative on its 53rd anniversary

Milann Fertility Center Celebrates World Breastfeeding Week with ‘Milann’s Embrace’ Initiative

DCN Dx to Showcase New Technologies at NextGen Dx 2024